Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health announced it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on February 25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health announced it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on February 25, 2021. The presentation will be accessible via a live webcast on the Company's website, with a replay available for 90 days afterwards.
Radius is focused on developing endocrine therapeutics, with its lead product TYMLOS® approved for treating high-risk postmenopausal women with osteoporosis. The company has additional investigational drugs targeting osteoporosis and hormone-receptor positive breast cancer.
Details
News Market Reaction – RDUS
The recorded move for RDUS in the trading session of this news was +0.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.
A live webcast of the presentation will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.
Investor & Media Relations Contact:
Peter Schwartzman
Email:investor-relations@radiuspharm.com
Phone: (617) 583-2017
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.